The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
The Failure of Solanezumab — How the FDA Saved Taxpayers Billions
Abstract
The failure of solanezumab offers a window into the U.S. drug regulatory system, particularly in the context of the 21st Century Cures Act and the national debate about the role of the FDA. The solanezumab story is an important case of a regulatory system that worked.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the expedition3 trial (NCT01900665), aimed at further validating the drug’s efficacy in patients with mild AD, the drug was declared unsuccessful in 2016, as it failed to meet its primary endpoints.457–459”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [457]
Citations
Cites
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Kazi, D. S., Moran, A. E., Coxson, P. G., Penko, J., Ollendorf, D. A., Pearson, S. D., Tice, J. A., Guzman, D., & Bibbins-Domingo, K. (2016) · JAMA · doi:10.1001/jama.2016.11004 · Cited by 382
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Park, J.-H., Ju, Y. H., Choi, J. W., Song, H. J., Jang, B. K., Woo, J., Chun, H., Kim, H. J., Shin, S. J., Yarishkin, O., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav0316 · Cited by 216
Can an Infection Hypothesis Explain the Beta Amyloid Hypothesis of Alzheimer’s Disease?
Fulop, T., Witkowski, J. M., Bourgade, K., Khalil, A., Zerif, E., Larbi, A., Hirokawa, K., Pawelec, G., Bocti, C., Lacombe, G., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00224 · Cited by 198
Role of the peripheral innate immune system in the development of Alzheimer's disease
Page, A. Y. L., Dupuis, G., Frost, E. H., Larbi, A., Pawelec, G., Witkowski, J. M., & Fülöp, T. (2017) · Experimental Gerontology · doi:10.1016/j.exger.2017.12.019 · Cited by 175
“A number of recently published reports have suggested alternative causes of AD because all clinical studies that have attempted to modulate the concentration of Aβ in the brain have failed to show any significant clinical benefit (Mehta et al., 2017; Sacks et al., 2017).”
Alzheimer’s disease as oligomeropathy
Ono, K. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2017.08.010 · Cited by 129
Metadata
- Authors
- Sacks, C. A., Avorn, J., & Kesselheim, A. S.
- Affiliations
- Brigham and Women's Hospital (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-05-04
- Volume
- 376
- Issue
- 18
- Pages
- 1706-1708
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2611277309
- Cited by
- 55
- References
- 2
- Citations by year
- 2026: 3 · 2024: 4 · 2023: 2 · 2022: 2 · 2021: 11 · 2020: 4 · 2019: 9 · 2018: 12 · 2017: 8
- FWCI
- 6.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Healthcare Regulation
- Keywords
- solanezumab, FDA oversight, 21st Century Cures Act, drug approval, drug development costs
- MeSH terms
- Alzheimer Disease, Dementia, Humans, United States, United States Food and Drug Administration, Randomized Controlled Trials as Topic, Drug Costs, Cost Savings, Treatment Failure, Drug Approval, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Failure of Solanezumab — How the FDA Saved Taxpayers Billions. https://app.cochat.ai/papers/10.1056/nejmp1701047
- The paper
- Sacks, C. A., Avorn, J., & Kesselheim, A. S. (2017). The Failure of Solanezumab — How the FDA Saved Taxpayers Billions. New England Journal of Medicine. https://doi.org/10.1056/nejmp1701047
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.